Journal article
Minocycline: Therapeutic potential in psychiatry
OM Dean, J Data-Franco, F Giorlando, M Berk
CNS Drugs | ADIS INT LTD | Published : 2012
Abstract
Pharmacological interventions to treat psychiatric illness have previously focused on modifying dysfunctional neurotransmitter systems to improve symptoms. However, imperfect understanding of the aetiology of these heterogeneous syndromes has been associated with poor treatment outcomes for many individuals. Growing evidence suggests that oxidative stress, inflammation, changes in glutamatergic pathways and neurotrophins play important roles in many psychiatric illnesses including mood disorders, schizophrenia and addiction. These novel insights into pathophysiology allow new treatment targets to be explored. Minocycline is an antibiotic that can modulate glutamate-induced excitotoxicity, an..
View full abstractGrants
Funding Acknowledgements
No sources of funding were used to prepare this review. MB has received grant/research support from the NIH, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier; has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck and Servier. FG has received grant/research support from the ASBD, AstraZeneca, Pfizer and the RANZCP. OD has received grant/research support from Simons Autism Foundation, Stanley Medical Research Institute, NHMRC and an ASBD/Servier grant. JF has no potential conflicts of interest.